RankingsLogo

Gilead Sciences, Inc.

Gilead Sciences, Inc. is a Humankind 100 company whose ranking is based on its Humankind Value, a proprietary metric that provides an estimate of the overall dollar amount a company creates for investors, consumers, employees, and society at large.

Gilead Sciences, Inc. is a biopharmaceutical company that researches and develops treatments and drugs. Its work has helped to treat HIV/AIDS, heart and liver diseases, cancers, respiratory diseases, and more.

Ticker: GILD

Humankind Value: $191.7 B

Revenue: $27.6 B

Market Cap: $81.2 B

Badge100_2024
Positive and negative impacts of companies graphic.

(All values are in US Dollars, where M=Million, B=Billion, T=Trillion.)

Gilead Sciences, Inc. is a net-positive Humankind Value company, primarily due to its contributions to Healthcare R&D ($103.7 B), Pharmaceuticals ($80.7 B), and Economic Value ($6.5 B). Positive value from Healthcare R&D and Pharmaceuticals includes the impact of an estimated 3,500,000 additional years lived by people worldwide. However, there is room for improvement with respect to Greenhouse Gases (-$1.8 B) and Air Pollution (-$226.5 M). The company’s direct business activities are responsible for its impacts on Healthcare R&D, Pharmaceuticals, Economic Value, Greenhouse Gases, and Air Pollution.

How the Humankind Value Methodology Drives the Rankings

We take a quantitative, data-driven approach to estimating the economic impact that companies have on investors, customers, employees, and society at large, rolling social responsibility into a single dollar value that we use to represent what a company is contributing to humanity. As far as we can tell, we're the first ones doing it this way.

LEARN MORE ABOUT OUR RESEARCH
How Methodology Drives the Rankings